720 related articles for article (PubMed ID: 19954925)
1. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure.
Scolletta S; Biagioli B
Biomed Pharmacother; 2010 Mar; 64(3):203-7. PubMed ID: 19954925
[TBL] [Abstract][Full Text] [Related]
2. Metabolic remodelling of the failing heart: beneficial or detrimental?
van Bilsen M; van Nieuwenhoven FA; van der Vusse GJ
Cardiovasc Res; 2009 Feb; 81(3):420-8. PubMed ID: 18854380
[TBL] [Abstract][Full Text] [Related]
3. Endogenous activation of mitochondrial KATP channels protects human failing myocardium from hydroxyl radical-induced stunning.
Maack C; Dabew ER; Hohl M; Schäfers HJ; Böhm M
Circ Res; 2009 Oct; 105(8):811-7. PubMed ID: 19729596
[TBL] [Abstract][Full Text] [Related]
4. Heart metabolic disturbances in cardiovascular diseases.
Carvajal K; Moreno-Sánchez R
Arch Med Res; 2003; 34(2):89-99. PubMed ID: 12700003
[TBL] [Abstract][Full Text] [Related]
5. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease.
Beadle RM; Frenneaux M
Heart; 2010 Jun; 96(11):824-30. PubMed ID: 20478861
[TBL] [Abstract][Full Text] [Related]
6. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
Lopaschuk GD
Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):228-30. PubMed ID: 16959756
[TBL] [Abstract][Full Text] [Related]
7. Myocardial substrate metabolism in the normal and failing heart.
Stanley WC; Recchia FA; Lopaschuk GD
Physiol Rev; 2005 Jul; 85(3):1093-129. PubMed ID: 15987803
[TBL] [Abstract][Full Text] [Related]
8. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
[TBL] [Abstract][Full Text] [Related]
9. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.
Jaswal JS; Keung W; Wang W; Ussher JR; Lopaschuk GD
Biochim Biophys Acta; 2011 Jul; 1813(7):1333-50. PubMed ID: 21256164
[TBL] [Abstract][Full Text] [Related]
10. Effect of ischemic preconditioning on mitochondrial oxidative phosphorylation and high energy phosphates in rat hearts.
Kobara M; Tatsumi T; Matoba S; Yamahara Y; Nakagawa C; Ohta B; Matsumoto T; Inoue D; Asayama J; Nakagawa M
J Mol Cell Cardiol; 1996 Feb; 28(2):417-28. PubMed ID: 8729072
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial oxidative stress and dysfunction in myocardial remodelling.
Tsutsui H; Kinugawa S; Matsushima S
Cardiovasc Res; 2009 Feb; 81(3):449-56. PubMed ID: 18854381
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure.
Fragasso G
Int J Clin Pract; 2007 Apr; 61(4):603-10. PubMed ID: 17394434
[TBL] [Abstract][Full Text] [Related]
13. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
Lopaschuk GD
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
[TBL] [Abstract][Full Text] [Related]
14. Diazoxide protects mitochondria from anoxic injury: implications for myopreservation.
Ozcan C; Holmuhamedov EL; Jahangir A; Terzic A
J Thorac Cardiovasc Surg; 2001 Feb; 121(2):298-306. PubMed ID: 11174735
[TBL] [Abstract][Full Text] [Related]
15. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload.
Doenst T; Pytel G; Schrepper A; Amorim P; Färber G; Shingu Y; Mohr FW; Schwarzer M
Cardiovasc Res; 2010 Jun; 86(3):461-70. PubMed ID: 20035032
[TBL] [Abstract][Full Text] [Related]
16. Postischemic administration of succinate reverses the impairment of oxidative phosphorylation after cardiac ischemia and reperfusion injury.
Cairns CB; Ferroggiaro AA; Walther JM; Harken AH; Banerjee A
Circulation; 1997 Nov; 96(9 Suppl):II-260-5. PubMed ID: 9386108
[TBL] [Abstract][Full Text] [Related]
17. K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation.
Ford WR; Lopaschuk GD; Schulz R; Clanachan AS
Br J Pharmacol; 1998 Jun; 124(4):639-46. PubMed ID: 9690854
[TBL] [Abstract][Full Text] [Related]
18. Effective pharmacotherapy against oxidative injury: alternative utility of an ATP-sensitive potassium channel opener.
Ozcan C; Terzic A; Bienengraeber M
J Cardiovasc Pharmacol; 2007 Oct; 50(4):411-8. PubMed ID: 18049309
[TBL] [Abstract][Full Text] [Related]
19. [Myocardial metabolism abnormalities during ischemia and reperfusion].
Argaud L; Ovize M
Arch Mal Coeur Vaiss; 2000 Jan; 93(1):87-90. PubMed ID: 11227723
[TBL] [Abstract][Full Text] [Related]
20. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
Wang W; Lopaschuk GD
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1123-34. PubMed ID: 18035928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
